Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Front Biosci ; 13: 5138-54, 2008 May 01.
Article in English | MEDLINE | ID: mdl-18508576

ABSTRACT

Resistance to chemotherapy ('drug resistance') is a fundamental problem that limits the effectiveness of many chemotherapies currently used to treat cancer. Drug resistance can occur due to a variety of mechanisms, such as increased drug inactivation, drug efflux from cancer cells, enhanced repair of chemotherapy-induced damage, activation of pro-survival pathways and inactivation of cell death pathways. In this article, we review some of the major mechanisms of drug resistance and discuss how new molecularly-targeted therapies are being increasingly used to overcome these resistance mechanisms.


Subject(s)
Drug Resistance, Neoplasm , Neoplasms/drug therapy , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Cell Death/drug effects , DNA Damage , DNA Repair/drug effects , Humans , Neoplasms/genetics , Neoplasms/pathology , Treatment Outcome
2.
Clin Cancer Res ; 10(10): 3562-71, 2004 May 15.
Article in English | MEDLINE | ID: mdl-15161716

ABSTRACT

Fas (CD95/Apo-1) is a member of the tumor necrosis factor receptor family. Receptor binding results in activation of caspase 8, leading to activation of proapoptotic downstream molecules. We found that expression of Fas was up-regulated >10-fold in MCF-7 breast and HCT116 and RKO colon cancer cell lines after treatment with IC(60) doses of 5-fluorouracil (5-FU) and raltitrexed (RTX). Combined treatment with the agonistic Fas antibody CH-11 and either 5-FU or RTX resulted in a highly synergistic induction of apoptosis in these cell lines. Similar results were obtained for another antifolate, Alimta. Induction of thymidylate synthase expression inhibited Fas induction in response to RTX and Alimta, but not in response to 5-FU. Furthermore, thymidylate synthase induction abrogated the synergy between CH-11 and both antifolates but had no effect on the synergistic interaction between 5-FU and CH-11. Inactivation of p53 in MCF-7 and HCT116 cell lines blocked 5-FU- and antifolate-mediated up-regulation of Fas. Furthermore, Fas was not up-regulated in response to 5-FU or antifolates in the p53-mutant H630 colon cancer cell line. Lack of Fas up-regulation in the p53-null and -mutant lines abolished the synergistic interaction between 5-FU and CH-11. Interestingly, synergy was still observed between the antifolates and CH-11 in the p53-null HCT116 and p53-mutant H630 cell lines, although this was significantly reduced compared with the p53 wild-type cell lines. Our results indicate that Fas is an important mediator of apoptosis in response to both 5-FU and antifolates.


Subject(s)
Antimetabolites/pharmacology , Apoptosis , Thymidylate Synthase/physiology , Tumor Suppressor Protein p53/physiology , fas Receptor/metabolism , Antibodies/pharmacology , Antibodies, Monoclonal/chemistry , Blotting, Northern , Blotting, Western , Cell Line, Tumor , Cell Survival , Dose-Response Relationship, Drug , Flow Cytometry , Fluorouracil/pharmacology , Folic Acid Antagonists/metabolism , Folic Acid Antagonists/pharmacology , Genes, p53 , Humans , Inhibitory Concentration 50 , Mutation , Oligonucleotide Array Sequence Analysis , Protein Binding , Signal Transduction , Tetracycline/pharmacology , Transgenes , Tumor Suppressor Protein p53/metabolism , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...